ImmuneBridge
Next generation allogenic NK cell therapy platform
ImmuneBridge is developing the next generation of allogeneic cellular medicines, starting with NK cell-based immunotherapies. ImmuneBridge’s proprietary expansion technology amplifies cord blood-derived immune stem cells while maintaining full immune multipotency—to create a consistent and abundant cellular source for immunotherapies. Based in San Francisco, ImmuneBridge is led by co-founders Peretz Partensky and Jesse Cotari and backed by M Ventures and Insight Partners.
